Shots:
- The companies collaborated to assess Turning Point’s elzovantinib (TPX-0022) in combination with EQRx’s aumolertinib in patients with EGFR mutant MET-amplified advanced NSCLC
- Turning Point will sponsor and conduct a P-Ib/II clinical trial to evaluate the safety, tolerability and preliminary efficacy of the combination regimen and will assume all costs associated with the trial whereas EQRx will provide aumolertinib at no cost
- Turning Point is planning to initiate the clinical trial in 2022, pending the filing of an IND application by the US FDA. Preclinical data suggested the combination of MET and EGFR inhibition has the potential to increase anti-tumor activity based on complementary mechanisms
Click here to read full press release/ article | Ref: Globe Newswire | Image: Turning Point
The post Turning Point and EQRx Collaborate to Evaluate Elzovantinib + Aumolertinib in Patients with EGFR Mutant Met-Amplified Advanced NSCLC first appeared on PharmaShots.
